Innovative mRNA Strategies to Encode CD19/CD3 T cell Engagers(Abogen Biosciences)

N/A

Report date: 2024/03/21 15:56:21

Base Information

Drug NameInnovative mRNA Strategies to Encode CD19/CD3 T cell Engagers(Abogen Biosciences)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > mRNA
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAbogen Biosciences Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAbogen Biosciences Co Ltd
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A